Aimmune Therapeutics Inc (NASDAQ:AIMT) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 3,820,122 shares, an increase of 49.0% from the February 15th total of 2,563,758 shares. Based on an average daily volume of 3,082,781 shares, the short-interest ratio is presently 1.2 days. Approximately 23.8% of the company’s shares are sold short.
In related news, insider Douglas T. Sheehy sold 3,523 shares of the stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $36.52, for a total value of $128,659.96. Following the completion of the transaction, the insider now directly owns 32,500 shares in the company, valued at approximately $1,186,900. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Douglas T. Sheehy sold 1,875 shares of the stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $39.44, for a total transaction of $73,950.00. Following the completion of the transaction, the insider now owns 1,875 shares of the company’s stock, valued at $73,950. The disclosure for this sale can be found here. Over the last ninety days, insiders bought 58,093 shares of company stock valued at $1,858,976 and sold 133,968 shares valued at $5,073,180. Company insiders own 17.59% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. First Republic Investment Management Inc. bought a new stake in Aimmune Therapeutics during the 4th quarter valued at about $202,000. SG Americas Securities LLC increased its stake in Aimmune Therapeutics by 54.7% during the 3rd quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 2,979 shares in the last quarter. Virtu Financial LLC bought a new stake in Aimmune Therapeutics during the 4th quarter valued at about $239,000. Daiwa SB Investments Ltd. increased its stake in Aimmune Therapeutics by 44.5% during the 4th quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 2,245 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Aimmune Therapeutics during the 4th quarter valued at about $282,000. Institutional investors and hedge funds own 62.04% of the company’s stock.
Several research analysts recently issued reports on AIMT shares. BidaskClub upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Roth Capital started coverage on shares of Aimmune Therapeutics in a research note on Monday, November 20th. They issued a “buy” rating and a $60.00 price target for the company. Credit Suisse Group set a $45.00 price target on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 11th. Cantor Fitzgerald reiterated a “buy” rating on shares of Aimmune Therapeutics in a research note on Tuesday, February 20th. Finally, Deutsche Bank set a $30.00 price target on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, February 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $57.22.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2018/03/13/aimmune-therapeutics-inc-aimt-short-interest-up-49-0-in-february.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.